FDA
-
-
-
-
-
-
-
Histogenics (HSGX) Reports Update on FDA Discussion of NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
-
-
-
-
-
-
-
Histogenics (HSGX) Announces Proposed Common Share Public Offering
-
-
-
-
-
-
-
Histogenics Corp. (HSGX) PT Lowered to $3.50 at Cowen
-
-
-
-
-
-
-
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
-
-
-
-
-
-
-
Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
-
-
-
-
-
-
-
Histogenics (HSGX) Announces Agreement With Japan PMDA on Regulatory Pathway for NeoCart
-
-
-
-
-
251,866 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All